Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 2, 2024

Primary Completion Date

December 15, 2025

Study Completion Date

December 15, 2026

Conditions

Hematologic MalignancyLarge B-cell LymphomaAcute Lymphoblastic LeukemiaMantle Cell LymphomaMultiple MyelomaDiffuse Large B Cell Lymphoma

Interventions

BIOLOGICAL

autologous hematopoietic stem cells added to planned CAR T

Autologous hematopoietic stem cells (aHSCs) infused on Day 10 after CAR T (any FDA-approved CAR T product) infusion on Day 0.

Trial Locations (1)

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors

lead

Joshua Sasine, MD, PhD

OTHER